Wire · regulatory
US Treasury proposes China biotech investment curbs, with questions for NewCo deals
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 23 October 2026 · Fusion42 review
The US Treasury proposed new restrictions to limit US investments in biotechnology firms in China and other countries of concern, targeting equity acquisitions, joint ventures, and strategic investments while largely exempting conventional pharmaceutical licensing deals. This expands the Outbound Investment Security Program to cover biotechnology alongside semiconductors, AI, and quantum technologies.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.
◆ ◆ The Wire takeaway
You face fresh limits on US biotech investments linked to China and allies, changing who you can partner with or take funding from this year. Adjust your deal structures and investor profiles now before the rules lock down cross-border equity arrangements.
◆ Coverage
2 sources · 23 Oct 2026
◆ Related on Wire
◆ Topics